POLE and cancer: Of 109 patients with grade 3 tumors, there were no recurrences or cancer deaths in the 15 (13.7%) POLE-mutant case, compared with 29 (30.9%) relapses and 25 (26.6%) EC deaths in the remaining 94 women (Figure 2, A and B), reflected in statistically significantly improved RFS in univariable analysis (HR = 0.09, 95% CI = 0.001 to 0.66, P = .01) and, following adjustment for other prognostic variables in multivariable analysis (HR = 0.11, 95% CI = 0.001 to 0.84, P = .03) (Table 3; Supplementary Tables 8 and 9, available online).